Serotonin and beyond: Therapeutics for major depression

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 368, Issue 1615, 2013, Pages

  Blier, Pierre ^a   El Mansari, Mostafa ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Autoreceptor; Drug combination; Electrophysiology; Neurotransmission; Remission; Serotonin

Indexed keywords

BIOCHEMISTRY; BRAIN; DISEASE TREATMENT; DRUG; HORMONE; MEDICINE; MENTAL HEALTH; NERVOUS SYSTEM DISORDER; NEUROLOGY; PHYSIOLOGY;

ANTIDEPRESSANT AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; NORADRENALIN; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

ANIMAL; DOPAMINERGIC NERVE CELL; DRUG EFFECT; ELECTROPHYSIOLOGY; GENETICS; HIPPOCAMPUS; HUMAN; MAJOR DEPRESSION; METABOLISM; PATHOLOGY; REVIEW; SEROTONINERGIC NERVE CELL; SYNAPTIC TRANSMISSION;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOPAMINE AGONISTS; DOPAMINERGIC NEURONS; ELECTROPHYSIOLOGICAL PHENOMENA; HIPPOCAMPUS; HUMANS; NOREPINEPHRINE; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONERGIC NEURONS; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SYNAPTIC TRANSMISSION;

EID: 84883885115     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2012.0536     Document Type: Review

References (64)

1. Collins PY, Patel V, Joestl SS, March D, Insel TR, Daar AS. 2011 Grand challenges in global mental health. Nature 475, 27-30. (doi:10.1038/475027a)
2. World Health Organization. 2008 The global burden of diseases. 2004 Update, part 4, pp. 40-51. Geneva, Switzerland: WHO Press.
3. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. 2007 Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 370, 851-858. (doi:10.1016/S0140-6736(07)61415-9)
4. Frasure-Smith N, Lespérance F, Gravel G, Masson G, Juneau M, Talajic M, Bourassa MG. 2000 Social support, depression, and mortality during the first year after myocardial infarction. Circulation 101, 1919-1924. (doi:10.1161/01.CIR.101.16.1919)
5. Coppen A. 1967 The biochemistry of affective disorders. Br. J. Pharmacol. 113, 1237-1264. (doi:10.1192/bjp.113.504.1237)
6. Delgado P, Charney DS, Price LH, Landis H, Heninger GS. 1989 Neuroendocrine and behavioral effects of dietary tryptophan restriction in healthy subjects. Life Sci. 45, 2323-2332. (doi:10.1016/0024-3205(89)90114-8)
7. Benkelfat C, Ellenbogen MA, Dean P, Palmour R, Young S. 1994 Mood-lowering effect of tryptophan depletion. Enhanced susceptibility in young men at genetic risk for major affective disorders. Arch. Gen. Psychiat. 51, 687-697. (doi:10.1001/archpsyc.1994.03950090019003)
8. Chaput Y, de Montigny C, Blier P. 1991 Presynaptic and postsynaptic modifications of the serotonin system by long-term administration of antidepressant treatments: an in vivo electrophysiologic study in the rat. Neuropsychopharmacology 5, 219-229.
9. Haddjeri N, Blier P, de Montigny C. 1998 Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors. J. Neurosci. 18, 10150-10156.
10. Caspi A et al. 2003 Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301, 386-389. (doi:10.1126/science.1083968)
11. Risch N et al. 2009 Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. J. Am. Med. Assoc. 301, 2462-2471. (doi:10.1001/jama.2009.878)
12. Kragh K, Burmeister M, Shedden K, Sen S. 2011 The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation. Arch. Gen. Psychiat. 68, 444-454. (doi:10.1001/archgenpsychiatry.2010.189)
13. de Montigny C, Aghajanian GK. 1978 Tricyclic antidepressants: long term treatment increases responsivity of rat forebrain neurons to serotonin. Science 202, 1301-1306. (doi:10.1126/science. 725608)
14. Menkes DB, Aghajanian GK. 1980 Chronic antidepressant treatment enhances a-adrenergic and serotonergic responses in the facial motor nucleus. Life Sci. 27, 45-55. (doi:10.1016/0024-3205(80)90018-1)
15. Menkes DB, Aghajanian GK. 1981 A1-adrenoceptormediated responses in the lateral geniculate nucleus are enhanced by chronic antidepressant treatment. Eur. J. Pharmacol. 74, 27-35. (doi:10.1016/0014-2999(81)90319-8)
16. Wang RX, Aghajanian GK. 1980 Enhanced sensitivity of amygdaloid neurons to serotonin and norepinephrine after chronic antidepressant treatment. Commun. Psychopharmacol. 4, 83-90.
17. de Montigny C. 1984 Electroconvulsive shock treatments enhance responsiveness of forebrain neurons to serotonin. J. Pharmacol. Exp. Ther. 228, 230-234.
18. Blier P, de Montigny C, Chaput Y. 1987 Modification of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. J. Clin. Psychopharmacol. 7(Suppl.), 24-35.
19. Blier P, de Montigny C. 1983 Electrophysiological investigations on the effect of repeated zimelidine administration on serotonergic neurotransmission in the rat. J. Neurosci. 3, 1270-1278.
20. Chaput Y, de Montigny C, Blier P. 1986 Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat brain. Naunyn Schmiedebergs Arch. Pharmacol. 333, 342-348. (doi:10.1007/BF005 00007)
21. Blier P, de Montigny C. 1980 Effect of chronic tricyclic antidepressant treatment on the serotoninergic autoreceptor. A microiontophoretic study in the rat. Naunyn Schmiedebergs Arch. Pharmacol. 314, 123-128. (doi:10.1007/BF00504527)
22. Dong J, de Montigny C, Blier P. 1999 Assessment of the serotonin reuptake blocking property of YM992: electrophysiological studies in the rat hippocampus and dorsal raphe. Synapse 34, 277-289. (doi:10.1002/(SICI)1098-2396(19991215)34:4,277::AIDSYN4.3.0.CO;2-W)
23. Blier P, de Montigny C. 1984 Serotonergic but not noradrenergic neurons in rat central nervous system adapt to long-term treatment with monoamine oxidase inhibitors. Neuroscience 16, 949-955. (doi:10.1016/0306-4522(85)90107-1)
24. Ghanbari R, El Mansari M, Blier P. 2011 Enhancement of serotonergic and noradrenergic neurotransmission in the rat hippocampus by sustained administration of bupropion. Psychopharmacology 217, 61-73. (doi:10.1007/s00213-011-2260-1)
25. Chenu F, El Mansari M, Blier P. 2013 Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine, and serotonin systems in the rat brain. Neuropsychopharmacology 38, 275-284. (doi:10.1038/npp.2012.140)
26. Manta S, Dong J, Debonnel G, Blier P. 2009 Enhancement of the function of rat serotonin and norepinephrine neurons by sustained vagus nerve stimulation. J. Psychiat. Neurosci. 34, 272-280.
27. Chernoloz O, El Mansari M, Blier P. 2009 Sustained administration of pramipexole modifies the spontaneous firing of dopamine, norepinephrine and serotonin neurons in the rat brain. Neuropsychopharmacology 34, 651-661. (doi:10.1038/npp.2008.114)
28. Chernoloz O, El Mansari M, Blier P. 2011 Long term administration of the dopamine D3/2 receptor agonist pramipexole increases dopamine and serotonin neurotransmission in the male rat forebrain. J. Psychiat. Neurosci. 37, 113-121. (doi:10.1503/jpn.110038)
29. Chernoloz O, El Mansari M, Blier P. 2012 Effects of sustained administration of quetiapine alone and in combination with a serotonin reuptake inhibitor on norepinephrine and serotonin transmission. Neuropsychopharmacology 37, 1717-1728. (doi:10.1038/npp.2012.18)
30. Tatsumi M, Groshan K, Blakely R, Richelson E. 1999 Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur. J. Pharmacol. 340, 249-258. (doi:10.1016/S0014-2999(97)01393-9)
31. Delgado PL, Miller HL, Salomon RM, Licinio J, Krystal JH, Moreno FA, Heninger GR, Charney DS. 1999 Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol. Psychiat. 46, 212-220. (doi:10.1016/S0006-3223(99)00014-1)
32. Cassidy F, Weiner RD, Cooper TB, Carroll BJ. 2010 Combined catecholamine and indolamine depletion following response to ECT. Br. J. Psychiat. 196, 493-494. (doi:10.1192/bjp.bp.109.070573)
33. Delgado PL, Moreno FA, Onate L, Gelenberg AJ. 2002 Sequential catecholamine and serotonin depletion in mirtazapine-treated depressed patients. Int. J. Neuropsychopharmacol. 5, 63-66. (doi:10.1017/S1461145702002778)
34. Szabo ST, de Montigny C, Blier P. 1997 Modulation of noradrenergic neuronal firing by selective serotonin reuptake blockers. Br. J. Pharmacol. 126, 568-571. (doi:10.1038/sj.bjp.0702343)
35. Dremencov E, El Mansari M, Blier P. 2007 Noradrenergic augmentation of escitalopram response by risperidone: electrophysiologic studies in the rat brain. Biol. Psychiat. 61, 671-678. (doi:10.1016/j.biopsych.2006.05.015)
36. Beique JC, de Montigny C, Blier P, Debonnel G. 1999 Venlafaxine: discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites. Synapse 32, 198-211. (doi:10.1002/(SICI)1098-2396(19990601)32:3,198::AIDSYN6.3.0. CO;2-2)
37. West CH, Ritchie JC, Boss-Williams KA, Weiss JA. 2009 Antidepressant drugs with differing pharmacological actions decrease activity of locus coeruleus neurons. Int. J. Neuropsychopharmacol. 12, 627-641. (doi:10.1017/S1461145708009474)
38. Kawahara Y, Kawahara H, Kaneko F, Tanaka M. 2007 Long-term administration of citalopram reduces basal and stress-induced extracellular noradrenaline levels in rat brain. Psychopharmacology 194, 73-81. (doi:10.1007/s00213-007-0826-8)
39. Blier P, Gobbi G, Turcotte JE, de Montigny C, Boucher N, Hébert C, Debonnel G. 2009 Mirtazapine and paroxetine in major depression: comparison of monotherapy versus their combination from treatment initiation. Eur. Neuropsychopharmacol. 19, 457-465. (doi:10.1016/j.euroneuro.2009.01.015)
40. Blier P, Ward HE, Tremblay P, Laberge L, Hébert C, Bergeron R. 2010 Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am. J. Psychiat. 167, 281-288. (doi:10.1176/appi.ajp.2009.09020186)
41. Ugedo L, Grenhoff J, Svensson TH. 1989 Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology 98, 45-50. (doi:10.1007/BF00442004)
42. Dremencov E, El Mansari M, Blier P. 2009 Effects of sustained serotonin reuptake inhibition on the firing of dopamine neurons in the rat ventral tegmental area. J. Psychiat. Neurosci. 34, 223-229.
43. Nelson JC, Mazure CM, Jatlow PI, Bowers MB, Price LH. 2004 Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol. Psychiat. 55, 296-300. (doi:10.1016/j.biopsych.2003.08.007)
44. Seager MA, Barth VN, Phebus LA, Rasmussen K. 2005 Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder. Psychopharmacology 181, 126-133. (doi:10.1007/s00213-005-2198-2)
45. Chernoloz O, El Mansari M, Blier P. 2009 Electrophysiological studies in the rat brain on the basis for aripiprazole augmentation of antidepressants in major depressive disorder. Psychopharmacology 206, 335-344. (doi:10.1007/s00213-009-1611-7)
46. Drevets WC. 1992 A functional anatomical study of unipolar depression. J. Neurosci. 12, 3628-3641.
47. Drevets WC. 2003 Neuroimaging abnormalities in the amygdala in mood disorders. Ann. NY Acad. Sci. 985, 420-424. (doi:10.1111/j.1749-6632.2003. tb07098.x)
48. Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, McGinnis S, Jerabek PA. 2000 Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol. Psychiat. 48, 830-843. (doi:10.1016/S0006-3223(00)01036-2)
49. Kennedy SH, Konarski JZ, Segal ZV, Lau MA, Bieling PJ, McIntyre RS, Mayberg HS. 2007 Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. Am. J. Psychiat. 164, 778-788. (doi:10.1176/appi.ajp.164.5.778)
50. Marek GJ, Aghajanian GK. 1999 5-HT2A receptor or alpha1-adrenoceptor activation induces excitatory postsynaptic currents in layer V pyramidal cells of the medial prefrontal cortex. Eur. J. Pharmacol. 367, 197-206. (doi:10.1016/S0014-2999(98) 00945-5)
51. Ghanbari R, El Mansari M, Blier P. 2010 Sustained administration of trazodone enhances serotonergic neurotransmission: in vivo electrophysiological study in the rat brain. J. Pharmacol. Exp. Ther. 305, 197-206. (doi:10.1124/jpet.110.169417)
52. Sheehan DV, Croft HA, Gossen ER, Levitt RJ, Brullé C, Bouchard S, Rozova A. 2009 Effects of sustained administration of quetiapine alone and in combination with a serotonin reuptake inhibitor on norepinephrine and serotonin transmission. Psychiatry 6, 20-33.
53. Mørk A et al. 2012 Pharmacological effects of Lu AA21004: a novel multimodal compound for the treatment of major depressive disorder. Pharmacol. Exp. Ther. 340, 666-675. (doi:10.1124/jpet.111.189068)
54. Alvarez E, Perez V, Dragheim M, Loft H, Artigas F. 2012 A double-blind, randomized, placebocontrolled, active reference study of LuAA21004 in patients with major depressive disorder. Int. J. Neuropsychopharmacol. 15, 589-600. (doi:10.1017/S1461145711001027)
55. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. 2000 Antidepressant effects of ketamine in depressed patients. Biol. Psychiat. 47, 351-354. (doi:10.1016/S0006-3223(99)00230-9)
56. Zarate Jr CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. 2006 A randomized trial of an N-methyl-Daspartate antagonist in treatment-resistant major depression. Arch. Gen. Psychiat. 63, 856-864. (doi:10.1001/archpsyc.63.8.856)
57. Diazgranados N et al. 2010 A randomized trial of an N-methyl-D-aspartate antagonist in treatmentresistant bipolar depression. Arch. Gen. Psychiat. 67, 793-802. (doi:10.1001/archgenpsychiatry.2010.90)
58. Rush AJ et al. 2006 Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a Star*D report. Am. J. Psychiat. 163, 1905-1917. (doi:10.1176/appi.ajp.163.11.1905)
59. Bunney BG, Bunney WE. 2012 Rapid-acting antidepressant strategies: mechanism of action. Int. J. Neuropsychopharmacol. 15, 695-713. (doi:10.1017/S1461145711000927)
60. Gardner JP, Fornal CA, Jacobs BL. 1997 Effects of sleep deprivation on serotonergic neuronal activity in the dorsal raphe nucleus of the freely moving cat. Neuropsychopharmacology 17, 72-81. (doi:10.1016/S0893-133X(97)00025-0)
61. Paul IA, Nowak G, Layer RT, Popik P, Skolnick P. 1993 Adaptation of the N-methyl-D-aspartate receptor complex following chronic antidepressant treatments. J. Pharmacol. Exp. Ther. 269, 95-102.
62. Holtzheimer PE, Mayberg HS. 2011 Deep brain stimulation for psychiatric disorders. Ann. Rev. Neurosci. 34, 289-307. (doi:10.1146/annurev neuro-061010-113638)
63. Etiévant A, Oosterhof CA, Bétry C, Abrial E, Lambas- Senas L, Scarna H, Lucas G, Haddjeri N. 2011 Antidepressant-like action of medial prefrontal cortex deep brain stimulation is modulated by glial system. Eur. Neuropsychopharmacol. 21(Suppl. 2), 405-406. (doi:10.1016/S0924-977X(11)70654-X)
64. Hamani C, Diwan M, Macedo CE, Brandao MI, Shumake J, Gonzalez-Lima F, Raymond R, Lozano AM, Fletcher PJ. 2010 Antidepressant-like effects of medial prefrontal cortex deep brain stimulation in rats. Biol. Psychiat. 67, 117-124. (doi:10.1016/j.biopsych.2009.08.025)